Quick Comparison
| Nicotine | PQQ | |
|---|---|---|
| Half-Life | 1-2 hours | 3-5 hours (plasma), but effects on mitochondrial biogenesis persist |
| Typical Dosage | Nootropic dose: 1-2 mg via gum, lozenge, or patch. Start with 0.5-1 mg if nicotine-naive. Patch: 7 mg patch cut into quarters (1.75 mg each). Use intermittently (2-3 times per week maximum) to avoid dependence. | Standard: 10-20 mg daily. Often combined with CoQ10 (100-300 mg) for synergistic mitochondrial support. Higher doses (40 mg) are used in some research settings. |
| Administration | Transdermal (patch), buccal (gum, lozenge), nasal (spray). Avoid smoking and vaping — the delivery method matters for health. | Oral (capsules, softgels). Best absorbed on an empty stomach. BioPQQ is the most studied branded form. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
Nicotine
Nicotine binds to nicotinic acetylcholine receptors (nAChRs), particularly the high-affinity alpha-4-beta-2 subtype predominant in the brain, causing conformational changes that open the cation channel and allow Na+ and Ca2+ influx, depolarizing the neuron. This triggers vesicular release of dopamine (VTA to nucleus accumbens and prefrontal cortex), norepinephrine (locus coeruleus), acetylcholine (basal forebrain), serotonin, and glutamate. Cognitive enhancement comes from increased acetylcholine in the prefrontal cortex and hippocampus (attention, working memory) and dopamine in mesocortical pathways (motivation, executive function). Nicotine upregulates BDNF through nAChR-mediated Ca2+ signaling and CREB activation, and has anti-inflammatory effects via microglial alpha-7 nAChRs. Neuroprotection may involve reduced excitotoxicity and enhanced neuronal survival pathways.
PQQ
PQQ activates PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master transcriptional regulator of mitochondrial biogenesis. PGC-1alpha coactivates NRF-1 and NRF-2, which drive expression of mitochondrial transcription factor A (TFAM) and nuclear-encoded mitochondrial genes—the process of creating new mitochondria in existing cells. This is unique among commercially available supplements. PQQ also provides antioxidant protection through extremely efficient redox cycling at the N5 position; it can undergo thousands of oxidation-reduction cycles before being exhausted, estimated at 5,000x the efficiency of vitamin C. PQQ activates the CREB (cAMP response element-binding protein) signaling pathway and may enhance NGF signaling, supporting BDNF expression, synaptic plasticity, and neuronal survival.
Risks & Safety
Nicotine
Common
Nausea, dizziness, hiccups, jaw soreness (gum), skin irritation (patch). Addictive with daily use.
Serious
Cardiovascular strain — increases heart rate and blood pressure. Avoid with cardiovascular disease. Nicotine toxicity at high doses (>60 mg).
Rare
Seizures at toxic doses, severe allergic reactions.
PQQ
Common
Very few — PQQ has an excellent safety profile at standard doses. Mild headache, fatigue initially.
Serious
No serious adverse effects documented.
Rare
Insomnia, irritability.
Full Profiles
Nicotine →
Nicotine — independent of tobacco — is one of the most potent cognitive enhancers known. It enhances attention, working memory, reaction time, and fine motor skills within minutes. Research shows it is neuroprotective and may reduce the risk of Parkinson's disease. Available as gum, patches, and lozenges for non-smokers seeking cognitive benefits without any tobacco exposure.
PQQ →
Pyrroloquinoline quinone is a redox cofactor that is the only known compound that can stimulate the growth of new mitochondria (mitochondrial biogenesis) in existing cells. Since mitochondrial density and function decline with age, PQQ addresses a root cause of age-related cognitive decline. It also provides potent antioxidant protection — estimated to be 5,000x more efficient at redox cycling than vitamin C.